Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.